Comparative efficacy and safety of second- and later-line BRAF-targeted regimens in BRAF V600E–mutant metastatic colorectal cancer: A systematic review and network meta-analysis
- DOI
- 10.1097/md.0000000000051468
- Published
- 2026-11-06
- Container
- Medicine
- Publisher
- Ovid Technologies (Wolters Kluwer Health)
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1097/md.0000000000051468,
title = {Comparative efficacy and safety of second- and later-line BRAF-targeted regimens in BRAF V600E–mutant metastatic colorectal cancer: A systematic review and network meta-analysis},
author = {Muhammad Arsalan and F.N.U. Sawaira and Irtaza Hassan and Taimoor Hassan and Mavra Khan and Muhammad Yasir and Shariq Hayat and Muhammad Junaid and Hassaan Qazi and Sarim Hassan Shahab and Aizaz Anwar and Owais Gul and Mohammad Al Diab Al Azzawi},
year = {2026},
journal = {Medicine},
doi = {10.1097/md.0000000000051468},
url = {https://doi.org/10.1097/md.0000000000051468}
}RIS
TY - JOUR TI - Comparative efficacy and safety of second- and later-line BRAF-targeted regimens in BRAF V600E–mutant metastatic colorectal cancer: A systematic review and network meta-analysis AU - Muhammad Arsalan AU - F.N.U. Sawaira AU - Irtaza Hassan AU - Taimoor Hassan AU - Mavra Khan AU - Muhammad Yasir AU - Shariq Hayat AU - Muhammad Junaid AU - Hassaan Qazi AU - Sarim Hassan Shahab AU - Aizaz Anwar AU - Owais Gul AU - Mohammad Al Diab Al Azzawi PY - 2026 JO - Medicine DO - 10.1097/md.0000000000051468 UR - https://doi.org/10.1097/md.0000000000051468 ER -
APA
Arsalan, M., Sawaira, F., Hassan, I., Hassan, T., Khan, M., Yasir, M., Hayat, S., Junaid, M., Qazi, H., Shahab, S. H., Anwar, A., Gul, O., & Azzawi, M. A. D. A. (2026). Comparative efficacy and safety of second- and later-line BRAF-targeted regimens in BRAF V600E–mutant metastatic colorectal cancer: A systematic review and network meta-analysis. Medicine. https://doi.org/10.1097/md.0000000000051468
Source records
- crossref · retrieved 2026-11-08T12:29:57.392Z